Omega Funds, a healthcare investor, completed the $15m Series A investment in Chord Therapeutics, a clinical stage biopharmaceutical company developing drugs for rare diseases. “The funding will enable Chord to execute its plan to obtain rigorous scientific evidence on the efficacy of CRD1 to treat severe conditions like NMOSD, with the goal of bringing patients an important new treatment option. I am excited to have the opportunity to work with patients, doctors, Tom and the Omega Team to realise this important ambition," Arthur Roach, Chord Therapeutics Founder and Director.